Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours

被引:62
作者
Altimari, A [1 ]
Fiorentino, M [1 ]
Gabusi, E [1 ]
Gruppioni, E [1 ]
Corti, B [1 ]
D'Errico, A [1 ]
Grigioni, WF [1 ]
机构
[1] Univ Bologna, Dept Hematol & Oncol, F Addari Inst Oncol, Pathol Unit, I-40138 Bologna, Italy
关键词
ErbB1; ErbB2; immunohistochemistry; primary liver tumours;
D O I
10.1016/S1590-8658(03)00077-X
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background. Molecular targets are needed for primary liver tumours. Aims. ErbB1 and ErbB2 expression was analysed in neoplastic and surrounding tissue in surgical specimens from 52 hepatocellular carcinomas and 48 intrahepatic cholangiocarcinomas, randomly chosen from cases surgically treated in this institution. Methods. ErbB1 and ErbB2 expression were evaluated immunohistochemically, the latter by Herceptest(R). Gene amplification of ErbB2 was tested by chromogenic in situ hybridisation. Results. In normal/cirrhotic non-neoplastic tissue, the ErbB1 (but not ErbB2) antibody commonly stained normal hepatocytes and mature intrahepatic ducts. In neoplastic tissue, moderate/strong ErbB1 immunostaining occurred in 43/52 (85%) hepatocellular carcinomas and 39/48 (81%) intra-hepatic cholangiocarcinomas. With ErbB2 Herceptest(R), 0/52 (0%) hepatocellular carcinomas and 2/48 (4%) intra-hepatic cholangiocarcinomas had treatable scores of 2+/3+ (chromogenic in situ hybridisation confirmed gene amplification in the latter two cases only). Neither ErbB1 nor ErbB2 expression correlated with any of the main clinical-pathologic features or survival. Conclusions. Although not related to prognosis, ErbB I could be a molecular target in a large percentage of patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma. Inclusion of anti-ErbB1 drugs such as ZD 1839 and c225 (and possibly also anti-ErbB2 drugs like Trastuzumab for a small subset of patients) in clinical trials is suggested. (C) 2003 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:332 / 338
页数:7
相关论文
共 36 条
[1]   Nonsurgical treatment of hepatocellular carcinoma [J].
Aguayo, A ;
Patt, YZ .
SEMINARS IN ONCOLOGY, 2001, 28 (05) :503-513
[2]  
Baselga J, 2001, EUR J CANCER, V37, pS16
[3]  
Baselga J, 1998, CANCER RES, V58, P2825
[4]  
BASELGA J, 2000, P AN M AM SOC CLIN, V19, P177
[5]  
Bridges AJ, 1999, CURR MED CHEM, V6, P825
[6]   RECEPTOR TYROSINE KINASES [J].
CADENA, DL ;
GILL, GN .
FASEB JOURNAL, 1992, 6 (06) :2332-2337
[7]  
CHOW NH, 1995, ANTICANCER RES, V15, P1055
[8]  
Ciardiello F, 2001, CLIN CANCER RES, V7, P2958
[9]  
Ciardiello F, 2000, CLIN CANCER RES, V6, P2053
[10]   Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents [J].
Ciardiello, F .
DRUGS, 2000, 60 (Suppl 1) :25-32